You just read:

SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID

News provided by

SCYNEXIS, Inc.

Apr 03, 2019, 08:30 ET